

# **Samrat Pharmachem Limited**

## Manufacturers & Exporters of Pharmaceutical Chemicals

CIN: L24230GJ1992PLC017820

#### Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4, Opp. PCI, Ankleshwar – 393 002,

Gujarat, India

Tel: (02646) 220774 Fax: (02646) 251291

Web: www.samratpharmachem.com

**Corporate Office** 

701/702, Business Square, M. A. Road, Andheri (West), Mumbai – 400 058, India.

Tel: (91-22) 26701050/1/2 Fax: (91-22) 26701053

E: contact@samratpharmachem.in

October 19, 2019

To,
Department of Corporate Services,
BSE Limited
25th Floor, P J Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sir,

#### Sub: Reconciliation of Share Capital Audit f.t.q.e. 30/09/2019

Pursuance to Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018, we are forwarding herewith a Certificate issued by Practicing Company Secretary after conducting Reconciliation of Share Capital Audit for the quarter ended September 30, 2019.

Thanking you,

Yours faithfully,

For Samrat Pharmachem Limited

Sandeep Prajapati Compliance Officer B.Com., L.L.M., F.C.S., A.C.I.S. (U.K.)., D.I.T.

### A. A. MULLA & ASSOCIATES

**Company Secretaries** 

3<sup>rd</sup> Floor, New Hari Leela House, 34/38, Mint Road, Opp. G.P.O., Mumbai – 400 001. Tel: 022-22644435 Fax: 022-22644434 M: 9892237418 Email: aqueelmulla@gmail.com

October 19, 2019

The Board of Directors,
M/s. Samrat Pharmachem Limited
Plot No. A2/3445,
GIDC, Phase 4,
Ankleshwar – 393 002,
Gujarat.

Dear Sir,

Pursuance to Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018, we are enclosing herewith a Certificate issued by us after conducting Reconciliation of Share Capital Audit for the quarter ended 30<sup>th</sup> September, 2019, as required under the said circular.

Please find the same in order & forward a copy of the same to the respective stock exchanges.

MUMBAI MEM. No. 2973

Yours faithfully,

For A.A. Mulla & Associates

**Company Secretaries** 

Aqueel A. Mulla

Proprietor

# **Reconciliation of Share Capital Audit Report**

(As per Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018).

Sr. No	Particulars	Details				
1.	For Quarter Ended	30 <sup>th</sup> September, 2019				
2.	ISIN	INE103E01016				
3.	Face Value	Rs. 10				
4.	Name of the Company	Samrat Pharmachem Limi	ted			
5.	Registered Office Address	Plot No. A2/3445, GIDC, Phase 4, Ankleshwar – 393 002, Gujarat.				
6.	Correspondence Address	701/702, Business Square, M. A. Road, Andheri (West), Mumbai – 400 058.				
7.	Tel No. & Fax No.	Tel : (022) 26701050 Fax : (022) 26701053				
8.	Email Address Website	contact@samratpharmachem.in www.samratpharmachem.com				
9.	Names of the stock exchanges where the company's securities are listed.	Mumbai				
10.	Issued Capital	No. of shares	% of total issued capital			
		30,89,700	100.00 %			
11.	Listed Capital (Exchange Wise) As per company records  It is same for all the exchanges	30,89,700 100.00 %				
12.	Held in dematerialized form in CDSL	4,02,639 13.03 %				
13.	Held in dematerialized form in NSDL	23,14,051 74.90 %				
14.	Physical	3,73,010 12.07 %				
15.	Total No. of shares (12+13+14)	30,89,700 100.00 %				
16.	Reasons for difference if any, between (10&11), (10&15), (11&15)	Nil				

17. Certifying the details of changes in share capital during the quarter under consideration as per table below:

Particulars ***	No. of shares	Applied / Not applied for listing	Listed on stock exchanges (specify names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Appr. Pending for SE (Specify Names)
Nil	Nil	Nil	Nil	Nil	Nil	Nil

<sup>\*\*\*</sup> Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, any other (to specify)

18.	Registrar of members is updated (Yes/No)	Yes
	If not, updated upto which date	Not Applicable A & ASSOC

19. Reference of previous quarter with regards to excess de-materialised shares, if any.	
20. Has the Company resolved the matter mentioned in Point No. 19 above in the current quarter? If not, reason why?	

21. Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:

Total No. of demat requests	No. of requests	No. of shares	Reason for delay
Confirmed after 21 days	0	0	-
Pending for more than 21 days	0	0	

22.	Name, Tel No., Fax No. & Membership No. of the Compliance Officer of the Co.	Name Tel No.		Mr. Sandeep Umashankar Prajapti (91) 9867228874
	140. of the comphance officer of the co.	Fax No.	:	-
		Membership	:	ACS-57823
		No.		
		Email	:	contact@samratpharmachem.in

23.	Name, Address, Tel No. & Fax No., Regn	Name	: A. A. Mulla & Associates
	No. of the Certifying CA/CS		Company Secretaries
		Address	: 3 <sup>rd</sup> Floor, New Hari Leela House,
			34/38, Mint Road, Opp. G.P.O.,
			Mumbai – 400 072.
		Tel No.	: (022) 22644435
		Fax No.	: (022) 22644434
		Cell No.	: 9892237418
		Email	: aqueelmulla@gmail.com

24.	Appointment of common agency for	Name	:	Link Intime India Pvt Ltd
	share registry work	Address	:	C-101, 247 Park,
				L. B. S. Marg, Vikhroli (West),
				Mumbai – 400 083, Maharashtra.
		Tel No.	:	(022) 49186000
		Fax No.	:	(022) 49186060
		Email	:	rnt.helpdesk@linkintime.co.in
		Kind Attn	:	Ms. Shweta Poojari

25. Any other detail that the CA/CS may like to provide (eg BIFR Company, de-listing from SE, etc)

Date: October 19, 2019

Place: Mumbai

For A. A. Mulla & Associates
Company Secretaries

MUMBAI

MEM. No. 2973 COP No. 3237

Maril

Aqueel A Mulla Proprietor C.P. No. 3237

CS No. 2973